Age at surgery, years (1351) |
59 (37–76) |
61 (43–76) |
58 (37–76) |
<0.001 |
PSA level, ng/mL (1343) |
4.9 (0.1–63.6) |
4.8 (0.1–24) |
5.0 (0.2–63.6) |
0.002 |
Biopsy Gleason score ≥7 (1342) |
433 (31.5) |
157 (31.5) |
265 (31.4) |
1.000 |
Clinical stage <T2 (1348) |
1009 (74.9) |
379 (75.5) |
630 (74.5) |
0.700 |
PSA velocity, ng/mL/year (616) |
1.32 (−251.4–41.5) |
1.57 (−52.1–28.3) |
1.25 (−251.4–41.5) |
0.160 |
PSA velocity >2 ng/mL/year (616) |
237 (38.5) |
99 (40.6) |
138 (37.1) |
0.400 |
Body mass index, kg/m2 (1347) |
27.0 (17.4–44.6) |
27.3 (19.3–44.1) |
26.6 (17.4–44.6) |
0.001 |
Pathology at RP |
|
|
|
|
Organ-confined (1339) |
1077 (80.4) |
406 (81.2) |
671 (80.0) |
0.620 |
Positive margins (1349) |
221 (16.4) |
69 (13.7) |
152 (18.0) |
0.048 |
Extracapsular extension (1349) |
251 (18.6) |
87 (17.3) |
164 (19.4) |
0.350 |
Seminal vesicle invasion (1348) |
57 (4.2) |
15 (3.0) |
42 (5.0) |
0.093 |
Lymph node metastases (1348) |
9 (0.7) |
2 (0.4) |
7 (0.8) |
0.500 |
Gleason score ≥7 (1345) |
653 (48.6) |
234 (46.8) |
419 (49.6) |
0.340 |
Prostate weight, g (1340) |
47.3 (16.0–557.3) |
48.1 (18.5–254.7) |
46.8 (16.0–557.3) |
0.260 |
% cancer (1276) |
8 (0.1–90) |
7.0 (0.1–75.0) |
9.0 (0.1–90.0) |
0.049 |
Tumour volume, mL (1276) |
3.7 (0.04–71.2) |
3.5 (0.06–50.2) |
3.7 (0.04–71.2) |
0.032 |